Ardsley Advisory Partners’s Cymabay Therapeutics CBAY Stock Holding History

Ardsley Advisory Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$102K	–	191
2019 Q3	$102K	Hold	20,000	–	–	0.02%	123
2019 Q2	$143K	Sell	20,000 -21,000	-51%	-$238K	0.02%	135
2019 Q1	$544K	Buy	41,000 +1,000	+3%	+$10.6K	0.1%	76
2018 Q4	$315K	Sell	40,000 -10,000	-20%	-$95.2K	0.08%	82
2018 Q3	$554K	Hold	50,000	–	–	0.07%	99
2018 Q2	$671K	Sell	50,000 -25,000	-33%	-$313K	0.1%	92
2018 Q1	$975K	Sell	75,000 -425,000	-85%	-$5.28M	0.15%	71
2017 Q4	$4.6M	Buy	500,000 +429,790	+612%	+$3.67M	0.56%	45
2017 Q3	$566K	Buy	70,210 +20,000	+40%	+$135K	0.08%	92
2017 Q2	$290K	Buy	50,210 +20,000	+66%	+$85.1K	0.05%	118
2017 Q1	$130K	Buy	30,210 +15,000	+99%	+$43K	0.02%	145
2016 Q4	$26K	Buy	+15,210	New	+$26.8K	﹤0.01%	123

Other funds holding CBAY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ardsley Advisory Partners's CBAY Position: Q4 2019 in Review

Ardsley Advisory Partners sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 20,000 shares — an estimated $102K sold.

Ardsley Advisory Partners first reported a position in CBAY in Q4 2016 and held it in 12 quarters. The position peaked at $4.6M in Q4 2017. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Ardsley Advisory Partners reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 20,000 Cymabay Therapeutics shares in Q4 2019, an estimated $102K.
Ardsley Advisory Partners first reported a position in Cymabay Therapeutics in Q4 2016 and held it in 12 quarters.
Ardsley Advisory Partners's Cymabay Therapeutics position peaked at $4.6M in Q4 2017.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Ardsley Advisory Partners's 13F filing for Q4 2019, filed 14 Feb 2020.